BioDlink International Company Ltd.

BioDlink International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule for the treatment of newly diagnosed glioblastoma multiforme or anaplastic astrocytoma that recurs or progresses after conventional treatment. In addition, the company develops TAB014 that has completed Phase III clinical trial for the treatment of wet age-related macular degeneration (wAMD); TAE020, which is in preclinical trial to treat acute myeloid leukemia; and TAC020, which is in preclinical trial for the treatment of various solid tumors. Further, it is involved in contract development and manufacturing organization (CDMO)/contract manufacture organization (CMO) business; and license-out of self-developed biological drugs. The company was formerly known as TOT BIOPHARM International Company Limited and changed its name to BioDlink International Company Limited in July 2025. BioDlink International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China. As of March 31, 2026, BioDlink International Company Limited operates as a subsidiary of WuXi XDC Cayman Inc.